1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Professor and Associate Dean for Research
Pharmaceutical Sciences
Phone (405) 271-6593 x47331
Fax (405) -271-7505
Office CPB 309
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 81. Awasthi S, Awasthi V. Distribution of dendritic cells after intranasal immunization in mice. Clinical Nuclear Medicine. 2005; 30 : 205
82. Awasthi S, Awasthi V, Magee D M, Coalson J J. Efficacy of antigen 2/proline-rich antigen cDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii. Journal of immunology (Baltimore, Md. : 1950). 2005; 175 : 3900-6
83. Awasthi S, Awasthi V. Regulation of pulmonary surfactant by growth factors and cytokines during lung injury . Research Signpost. 2002; 2 : 223-238
84. Awasthi S, Vivekananda J, Awasthi V, Smith D, King R J. CTP:phosphocholine cytidylyltransferase inhibition by ceramide via PKC-alpha, p38 MAPK, cPLA2, and 5-lipoxygenase. American journal of physiology. Lung cellular and molecular physiology. 2001; 281 : L108-18
85. Vivekananda J, Awasthi V, Awasthi S, Smith D B, King R J. Hepatocyte growth factor is elevated in chronic lung injury and inhibits surfactant metabolism. American journal of physiology. Lung cellular and molecular physiology. 2000; 278 : L382-92
Grants
- 1. Developing PPARĪ³ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
2. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
3. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
4. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
5. STTR Phase I: Cardiotropic Atorvastatin Liposomes for Myocardial Reperfusion Injury. NSF. Start Date: 2023. End Date: 2021.
Awards and Honors
- 6. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.
7. Indo-American Society of Nuclear Medicine. President. Date: 2010.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results